ndividual cohort studies may lack the sample size necessary for precise subgroup estimates of vascular risk. Whether women and men are at similar cigarette smoking-related stroke risk was uncertain. A meta-analysis of 81 cohorts, including almost 4 million persons, found both women (relative risk [RR], 1.83; 95% confidence interval [CI], 1.58-2.1) and men (RR, 1.67; 95% CI, 1.49-1.88) who are current cigarette smokers are at increased stroke risk with the risk similar regardless of sex (RR ratio for women versus men, 1.06; 95% CI, 0.99-1.13).
I
ndividual cohort studies may lack the sample size necessary for precise subgroup estimates of vascular risk. Whether women and men are at similar cigarette smoking-related stroke risk was uncertain. A meta-analysis of 81 cohorts, including almost 4 million persons, found both women (relative risk [RR], 1.83; 95% confidence interval [CI], 1.58-2.1) and men (RR, 1.67; 95% CI, 1.49-1.88) who are current cigarette smokers are at increased stroke risk with the risk similar regardless of sex (RR ratio for women versus men, 1.06; 95% CI, 0.99-1.13). 1 Another study confirmed the association between physical inactivity and stroke risk (hazard ratio [HR], 1.20; 95% CI, 1.02-1.42), an effect that was partially attenuated by traditional stroke risk factors (diabetes mellitus, hypertension, body mass index, alcohol use, and smoking; HR, 1.14; 95% CI, 0.95-1.37), suggesting that exercise might partially reduce the effect of other risk factors or reflect a healthy-user effect. 2 Up to one third of strokes are cryptogenic. A randomized trial found that 7 days of noninvasive cardiac-event monitoring, in addition to a standard evaluation, beginning within 7 days of stroke detected atrial fibrillation in 44% of patients compared with 4% having a standard evaluation alone (P<0.001). 3 Prolonged cardiac monitoring may reduce the proportion of patients with cryptogenic stroke resulting in more patients correctly diagnosed and treated.
Consistent with growing evidence of an association between vascular risk and cognitive impairment, analysis of data from a large population-based cohort found that having a poorer cardiovascular risk profile was associated with poorer cognitive function, an association that was present even in 35-to 44-year olds. 4 Better life-long cardiovascular health may pay additional dividends by reducing cognitive impairment.
Consistent with prior trials, the Stroke Prevention Study-3, a randomized trial comparing aspirin plus clopidogrel with aspirin alone for secondary stroke prevention after lacunar stroke, found no reduction in recurrent stroke (HR, 0.92; 95% CI, 0.72-1.16) or disabling or fatal stroke (HR, 1.06; 95% CI, 0.69-1.64) with dual antiplatelet therapy. 5 The risk of major hemorrhage was almost double (HR, 1.97; 95% CI, 1.41-2.71) and all-cause mortality was increased by half (HR, 1.52; 95% CI, 1.14-2.04). Long-term dual antiplatelet therapy is not advisable for secondary stroke prevention. A short, early course after transient ischemic attack or stroke, however, may be helpful. A meta-analysis of 14 randomized studies including 9012 patients with noncardioembolic stroke found that, compared with monotherapy, dual antiplatelet therapy (particularly aspirin and clopidogrel) reduced the risk of recurrent stroke by 31% (risk ratio, RR, 0.69; 95% CI, 0.60-0.80) and a composite of stroke, transient ischemic attack, acute coronary syndromes, and death by 29% (RR, 0.71; 95% CI, 0.63-0.81), but with a nonsignificant increase in major bleeding (RR, 1.35; 95% CI, 0.70-2.59). 6 Patients with asymptomatic carotid artery stenosis are often followed up with serial duplex ultrasound to identify progressive stenosis aiming to reduce stroke risk using carotid endarterectomy. The average annual ipsilateral stroke rate, however, was only 2.6% in asymptomatic patients who progressed from a baseline 70% to 99% stenosis 7 and 2.2% in those who progressed from a 50% to 69% stenosis 8 when given medical treatment alone. These rates were lower than expected and might be further reduced with more intensive medical therapy. Because of advances in medical therapy, an international, multidisciplinary group concluded that the great majority of asymptomatic patients with carotid stenosis would not benefit from either carotid endarterectomy or carotid angioplasty/stenting. 9 The same group concluded that carotid angioplasty/stenting for an average surgical risk symptomatic patient is not currently advisable given higher stroke and death rates with stenting compared with carotid endarterectomy. 9 The Cholesterol Treatment Trialists conducted a meta-analysis of 27 randomized trials comparing statin therapy with controls in patients at low risk of vascular events. 10 Stroke risk was reduced by 24% per 1.0 mmol/L reduction in lowdensity lipoprotein-cholesterol (RR, 0.76; 99% CI, 0·61-0·95) among those with a 5-year major vascular event risk <10%. New guidelines from the American College of Cardiology/ American Heart Association provide recommendations for cholesterol treatment for primary and secondary prevention of vascular events, including stroke, in adults. 11 Consistent with the Cholesterol Treatment Trialists meta-analysis, groups for whom statin therapy is recommended include those with a 10-year vascular risk (including stroke) of ≥7.5%. Measuring lipids to reach a specific low-density lipoprotein-cholesterol target was not thought necessary with the intensity of statin therapy based on vascular risk.
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Statin therapy to reduce the likelihood of vascular events among those whose risk is sufficiently high to warrant therapy is a proven approach for reducing stroke. Whether dietary supplementation with Ω-3 fatty acids reduces vascular risk is controversial. The Risk and Prevention Study Cooperative Group now reports no benefit of n-polyunsaturated fatty acids in reducing the cumulative rate of nonfatal stroke, nonfatal myocardial infarction, or death in a randomized study of 12 513 patients with multiple cardiovascular risk factors. 12 Providing a basis for the designation of Primary Stroke Centers, the provision of organized, multidisciplinary care for patients with acute ischemic stroke is associated with better outcomes. Two studies found that patients with intracerebral hemorrhage are just as likely to benefit from care in a Stroke Unit, one of the components of a Primary Stroke Center, as those with ischemic stroke. 13, 14 Similarly, care in a Primary Stroke Centers is associated with better outcomes for patients with intracerebral or subarachnoid hemorrhage compared with nonstroke center care. 15 Additional research is required to determine the components of Stroke Unit and Primary Stroke Center care having the greatest influence on patient outcomes.
Reducing early hospital readmissions is a goal of US healthcare reform. Older age, cardiovascular comorbidity, premorbid functional status, and having a serious adverse event while hospitalized are predictors of readmission within 30 days of stroke. 16, 17 Using US Agency for Healthcare Research and Quality criteria, however, only 1.7% of stroke discharges for Medicare beneficiaries were followed by a preventable early readmission. 16 Targeted, cost-effective strategies are needed to further reduce this rate.
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